Orforglipron, a daily GLP-1 receptor agonist pill, lowered HbA1c by up to 1.6% and body weight by 7.9% in a phase III trial ...

The FDA has approved Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has not been curative.

Osilodrostat, an oral cortisol synthesis inhibitor, was previously approved for treating adults with Cushing disease, a subtype of Cushing syndrome in which the hypercortisolemia is due to pituitary ...

Italian pharma major Recordati (RECI: MI) today announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the ...

a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of ...

Full Food and Drug Administration approval would allow the vaccine to be used more widely and could offer more reassurance to people looking for options besides the existing mRNA vaccines ...

Inebilizumab significantly reduced the risk of treated and AC-determined IgG4-RD flare by 87% compared with placebo. The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab ...